TW200426139A - 5-substituted-six-membered heteroaromatic glucokinase activators - Google Patents
5-substituted-six-membered heteroaromatic glucokinase activators Download PDFInfo
- Publication number
- TW200426139A TW200426139A TW092135035A TW92135035A TW200426139A TW 200426139 A TW200426139 A TW 200426139A TW 092135035 A TW092135035 A TW 092135035A TW 92135035 A TW92135035 A TW 92135035A TW 200426139 A TW200426139 A TW 200426139A
- Authority
- TW
- Taiwan
- Prior art keywords
- phenyl
- cyclopentyl
- chloro
- methanesulfonyl
- scope
- Prior art date
Links
- 125000001072 heteroaryl group Chemical group 0.000 title claims 5
- 102000030595 Glucokinase Human genes 0.000 title 1
- 108010021582 Glucokinase Proteins 0.000 title 1
- 239000012190 activator Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 83
- -1 nitro, cyano, fluorenyl Chemical group 0.000 claims 58
- 229910052799 carbon Inorganic materials 0.000 claims 19
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 18
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 6
- 150000001412 amines Chemical group 0.000 claims 5
- 150000001721 carbon Chemical group 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical group CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000011593 sulfur Substances 0.000 claims 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical group C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- QSHAGBNPQGXSBI-MRVPVSSYSA-N (2R)-2-(3-methyl-4-methylsulfonylphenyl)propanamide Chemical compound CS(=O)(=O)C1=C(C=C(C=C1)[C@H](C(=O)N)C)C QSHAGBNPQGXSBI-MRVPVSSYSA-N 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- JCDWETOKTFWTHA-UHFFFAOYSA-N methylsulfonylbenzene Chemical compound CS(=O)(=O)C1=CC=CC=C1 JCDWETOKTFWTHA-UHFFFAOYSA-N 0.000 claims 2
- SFDJOSRHYKHMOK-UHFFFAOYSA-N nitramide Chemical compound N[N+]([O-])=O SFDJOSRHYKHMOK-UHFFFAOYSA-N 0.000 claims 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims 1
- IRMJJWOCROUNFY-UHFFFAOYSA-N 3-cyclopentylpropanamide Chemical compound NC(=O)CCC1CCCC1 IRMJJWOCROUNFY-UHFFFAOYSA-N 0.000 claims 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- 102100037651 AP-2 complex subunit sigma Human genes 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- GWFNFZUTILMLPN-UHFFFAOYSA-N C(N)=N.CN Chemical compound C(N)=N.CN GWFNFZUTILMLPN-UHFFFAOYSA-N 0.000 claims 1
- SYRVLZWXDUKBHF-UHFFFAOYSA-N C1C2=C(C3=CC=CC=C31)C(=CC=C2)SC4=CC=CC5=C4C6=CC=CC=C6C5 Chemical compound C1C2=C(C3=CC=CC=C31)C(=CC=C2)SC4=CC=CC5=C4C6=CC=CC=C6C5 SYRVLZWXDUKBHF-UHFFFAOYSA-N 0.000 claims 1
- PNKUSGQVOMIXLU-UHFFFAOYSA-N Formamidine Chemical compound NC=N PNKUSGQVOMIXLU-UHFFFAOYSA-N 0.000 claims 1
- 101000806914 Homo sapiens AP-2 complex subunit sigma Proteins 0.000 claims 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims 1
- 241001674048 Phthiraptera Species 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 229940125782 compound 2 Drugs 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 claims 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 1
- 239000007789 gas Substances 0.000 claims 1
- 150000004820 halides Chemical group 0.000 claims 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000001294 propane Substances 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001732 pyren-2-yl group Chemical group [H]C1=C([H])C2=C([H])C([H])=C3C([H])=C(*)C([H])=C4C([H])=C([H])C(=C1[H])C2=C34 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 239000002689 soil Substances 0.000 claims 1
- 239000004575 stone Substances 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 229910052902 vermiculite Inorganic materials 0.000 claims 1
- 239000010455 vermiculite Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43280602P | 2002-12-12 | 2002-12-12 | |
| US52453103P | 2003-11-24 | 2003-11-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200426139A true TW200426139A (en) | 2004-12-01 |
Family
ID=32511672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW092135035A TW200426139A (en) | 2002-12-12 | 2003-12-11 | 5-substituted-six-membered heteroaromatic glucokinase activators |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7132425B2 (enExample) |
| EP (1) | EP1572670B1 (enExample) |
| JP (1) | JP4490285B2 (enExample) |
| KR (1) | KR100743890B1 (enExample) |
| AR (1) | AR046244A1 (enExample) |
| AT (1) | ATE370936T1 (enExample) |
| AU (1) | AU2003292229B2 (enExample) |
| BR (1) | BR0317268A (enExample) |
| CA (1) | CA2506441C (enExample) |
| CY (1) | CY1106989T1 (enExample) |
| DE (1) | DE60315886T2 (enExample) |
| DK (1) | DK1572670T3 (enExample) |
| ES (1) | ES2291697T3 (enExample) |
| HR (1) | HRP20050512A2 (enExample) |
| MX (1) | MXPA05006250A (enExample) |
| MY (1) | MY141521A (enExample) |
| NO (1) | NO330139B1 (enExample) |
| NZ (1) | NZ540298A (enExample) |
| PA (1) | PA8592001A1 (enExample) |
| PE (1) | PE20040801A1 (enExample) |
| PL (1) | PL377551A1 (enExample) |
| PT (1) | PT1572670E (enExample) |
| RU (1) | RU2310648C2 (enExample) |
| TW (1) | TW200426139A (enExample) |
| UY (1) | UY28121A1 (enExample) |
| WO (1) | WO2004052869A1 (enExample) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| WO2004050645A1 (en) | 2002-10-03 | 2004-06-17 | Novartis Ag | Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes |
| GB0226930D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| US7262196B2 (en) * | 2003-02-11 | 2007-08-28 | Prosidion Limited | Tri(cyclo) substituted amide glucokinase activator compounds |
| EP1735322B1 (en) | 2004-04-02 | 2011-09-14 | Novartis AG | Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful for the treatment of type 2 diabetes |
| BRPI0509543A (pt) | 2004-04-02 | 2007-09-18 | Novartis Ag | derivados de tiazolopiridina, condições farmacêuticas que contêm os mesmos e métodos para tratar condições mediadas por glucocinase |
| JP2008521864A (ja) * | 2004-12-03 | 2008-06-26 | トランステック・ファーマ、インコーポレイテッド | ヘテロ芳香族グルコキナーゼ活性化剤 |
| EP2301935A1 (en) | 2005-07-09 | 2011-03-30 | AstraZeneca AB (Publ) | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes |
| CA2621227A1 (en) * | 2005-08-31 | 2007-03-08 | Astellas Pharma Inc. | Thiazole derivative |
| JP2007063225A (ja) * | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| CN101272784A (zh) | 2005-09-29 | 2008-09-24 | 塞诺菲-安万特股份有限公司 | 苯基-和吡啶基-1,2,4-噁二唑酮衍生物、它们的制备方法和它们作为药物的用途 |
| GT200600429A (es) * | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
| GT200600428A (es) * | 2005-09-30 | 2007-05-21 | Compuestos organicos | |
| US20070197532A1 (en) * | 2005-11-18 | 2007-08-23 | Cao Sheldon X | Glucokinase activators |
| WO2007104034A2 (en) | 2006-03-08 | 2007-09-13 | Takeda San Diego, Inc. | Glucokinase activators |
| US8211925B2 (en) * | 2006-04-28 | 2012-07-03 | Transtech Pharma, Inc. | Benzamide glucokinase activators |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| EP2049518B1 (en) * | 2006-05-31 | 2011-08-31 | Takeda San Diego, Inc. | Indazole and isoindole derivatives as glucokinase activating agents. |
| FR2903985B1 (fr) | 2006-07-24 | 2008-09-05 | Sanofi Aventis Sa | Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| JP2009544648A (ja) | 2006-07-24 | 2009-12-17 | エフ．ホフマン−ラ ロシュ アーゲー | グルコキナーゼ活性化剤としてのピラゾール類 |
| FR2904316B1 (fr) | 2006-07-31 | 2008-09-05 | Sanofi Aventis Sa | Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique. |
| US20080107725A1 (en) * | 2006-10-13 | 2008-05-08 | Albano Antonio A | Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers |
| US7902248B2 (en) * | 2006-12-14 | 2011-03-08 | Hoffmann-La Roche Inc. | Oxime glucokinase activators |
| WO2008079787A2 (en) | 2006-12-20 | 2008-07-03 | Takeda San Diego, Inc. | Glucokinase activators |
| WO2008074694A1 (en) * | 2006-12-20 | 2008-06-26 | F. Hoffmann-La Roche Ag | Crystallization of glucokinase activators |
| TW200831081A (en) * | 2006-12-25 | 2008-08-01 | Kyorin Seiyaku Kk | Glucokinase activator |
| FR2910473B1 (fr) | 2006-12-26 | 2009-02-13 | Sanofi Aventis Sa | Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique. |
| EP2105435A4 (en) * | 2007-01-10 | 2011-06-15 | Mitsubishi Tanabe Pharma Corp | Hydrazone derivative |
| KR101538810B1 (ko) | 2007-02-09 | 2015-07-22 | 메타베이시스 테라퓨틱스, 인크. | 글루카곤 수용체의 길항제 |
| WO2008111473A1 (ja) * | 2007-03-07 | 2008-09-18 | Kyorin Pharmaceutical Co., Ltd. | グルコキナーゼ活性化物質 |
| WO2008116107A2 (en) * | 2007-03-21 | 2008-09-25 | Takeda San Diego, Inc. | Piperazine derivatives as glucokinase activators |
| JP2010523095A (ja) | 2007-04-04 | 2010-07-15 | エフ．ホフマン−ラ ロシュ アーゲー | 対応しているケトン類の酵素還元による２−アミノ−［５−（１（ｓ），２−ジヒドロキシエチル）又は−（ｋｓ）−ヒドロキシ−２−ハロエチル）］−ピラジン誘導体を製造するための方法 |
| JP2010524861A (ja) * | 2007-04-20 | 2010-07-22 | メルク フロスト カナダ リミテツド | ステアロイル−補酵素ａデルタ−９デサチュラーゼの阻害剤としての新規な複素環式芳香族化合物 |
| WO2009022179A2 (en) * | 2007-08-14 | 2009-02-19 | Astrazeneca Ab | Glucokinase activators in the treatment of osteoarthritis |
| AU2008310519B2 (en) * | 2007-10-08 | 2013-05-02 | Advinus Therapeutics Private Limited | Acetamide derivatives as glucokinase activators, their process and medicinal applications |
| KR20100113518A (ko) | 2008-01-18 | 2010-10-21 | 아스텔라스세이야쿠 가부시키가이샤 | 페닐아세트아미드 유도체 |
| US8258134B2 (en) * | 2008-04-16 | 2012-09-04 | Hoffmann-La Roche Inc. | Pyridazinone glucokinase activators |
| US7741327B2 (en) | 2008-04-16 | 2010-06-22 | Hoffmann-La Roche Inc. | Pyrrolidinone glucokinase activators |
| JP5449144B2 (ja) * | 2008-04-28 | 2014-03-19 | 杏林製薬株式会社 | シクロペンチルアクリル酸アミド誘導体 |
| BRPI0918004B8 (pt) | 2008-08-13 | 2021-05-25 | Metabasis Therapeutics Inc | compostos antagonistas e agonistas inversos de receptores de glucagon, composição farmacêutica e uso dos compostos |
| UA104742C2 (uk) * | 2008-12-19 | 2014-03-11 | Эли Лилли Энд Компани | Похідні арилциклопропілацетаміду, застосовні як активатори глюкокінази |
| US20110021570A1 (en) * | 2009-07-23 | 2011-01-27 | Nancy-Ellen Haynes | Pyridone glucokinase activators |
| US20110040091A1 (en) | 2009-08-13 | 2011-02-17 | Stephan Bachmann | Process for the preparation of (r)-2-phenyl propionic acid derivatives |
| US20110054174A1 (en) | 2009-08-28 | 2011-03-03 | Stephan Bachmann | Process for the preparation of a glucokinase activator compound |
| EP2493871B1 (en) | 2009-10-30 | 2014-09-03 | Domain Therapeutics | Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| US8222416B2 (en) | 2009-12-14 | 2012-07-17 | Hoffmann-La Roche Inc. | Azaindole glucokinase activators |
| ES2893699T3 (es) | 2010-03-31 | 2022-02-09 | Scripps Research Inst | Reprogramación de células |
| US8592396B2 (en) | 2010-04-14 | 2013-11-26 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
| US8178689B2 (en) | 2010-06-17 | 2012-05-15 | Hoffman-La Roche Inc. | Tricyclic compounds |
| AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
| ES2568260T3 (es) * | 2010-11-16 | 2016-04-28 | Acetylon Pharmaceuticals, Inc. | Compuestos de pirimidin hidroxi amida como inhibidores de proteína desacetilasa y métodos de uso de los mismos |
| US8470866B2 (en) | 2011-05-03 | 2013-06-25 | Hoffmann-La Roche Inc. | Isoindolinone derivatives |
| CN104093716B (zh) | 2011-10-31 | 2017-06-23 | 克赛农制药股份有限公司 | 联芳醚磺酰胺化合物及其作为治疗剂的用途 |
| ES2586213T3 (es) | 2011-10-31 | 2016-10-13 | Xenon Pharmaceuticals Inc. | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos |
| HK1209100A1 (en) | 2012-05-22 | 2016-03-24 | 基因泰克有限公司 | N-substituted benzamides and their use in the treatment of pain |
| KR101663436B1 (ko) | 2012-07-06 | 2016-10-06 | 제넨테크, 인크. | N-치환된 벤즈아미드 및 이의 사용 방법 |
| KR20150131233A (ko) | 2013-03-14 | 2015-11-24 | 제넨테크, 인크. | 치환된 트리아졸로피리딘 및 이의 사용 방법 |
| WO2014144545A2 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Substituted benzoxazoles and methods of use thereof |
| AU2014309251B2 (en) | 2013-08-23 | 2018-05-24 | Parion Sciences, Inc. | Dithiol mucolytic agents |
| JP6626437B2 (ja) | 2013-10-08 | 2019-12-25 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | ヒストンデアセチラーゼ阻害剤とＨｅｒ２阻害剤またはＰＩ３Ｋ阻害剤のいずれかの組み合わせ |
| ES2862126T3 (es) | 2013-10-10 | 2021-10-07 | Acetylon Pharmaceuticals Inc | Compuestos de pirimidín-hidroxiamida como inhibidores de histona desacetilasa |
| EP3060217B1 (en) | 2013-10-24 | 2022-06-08 | Mayo Foundation for Medical Education and Research | Treatment of polycystic diseases with an hdac6 inhibitor |
| CN105793238B (zh) | 2013-11-27 | 2019-12-24 | 基因泰克公司 | 经取代的苯甲酰胺及其使用方法 |
| EP2878339A1 (en) | 2013-12-02 | 2015-06-03 | Siena Biotech S.p.A. | SIP3 antagonists |
| US9949972B2 (en) | 2013-12-03 | 2018-04-24 | Acetylon Pharmaceuticals, Inc | Combinations of histone deacetylase inhibitors and immunomodulatory drugs |
| US9464073B2 (en) | 2014-02-26 | 2016-10-11 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors |
| WO2015191900A1 (en) | 2014-06-12 | 2015-12-17 | Ligand Pharmaceuticals, Inc. | Glucagon antagonists |
| EP3166939B1 (en) | 2014-07-07 | 2019-06-05 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| CN107205988A (zh) | 2014-07-07 | 2017-09-26 | 埃斯泰隆制药公司 | 利用组蛋白脱乙酰酶抑制剂治疗白血病 |
| LT3186257T (lt) | 2014-08-27 | 2019-04-25 | Prexton Therapeutics Sa | Nauji chromono oksimo dariniai ir jų panaudojimas kaip metabotropinių gliutamato receptorių alosterinių moduliatorių |
| US9937174B2 (en) | 2014-12-05 | 2018-04-10 | University of Modena and Reggio Emilia | Combinations of histone deacetylase inhibitors and bendamustine |
| MX387071B (es) * | 2015-01-30 | 2025-03-19 | Parion Sciences Inc | Agentes mucolíticos de monotiol novedosos |
| EP3288548A4 (en) | 2015-04-30 | 2018-10-31 | Parion Sciences, Inc. | Novel prodrugs of dithiol mucolytic agents |
| US10179767B2 (en) | 2015-05-22 | 2019-01-15 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| US10272084B2 (en) | 2015-06-01 | 2019-04-30 | Regenacy Pharmaceuticals, Llc | Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy |
| CN108349993A (zh) | 2015-08-27 | 2018-07-31 | 普雷克斯顿医疗股份公司 | 用于左旋多巴诱导的运动障碍疗法的脑-穿透剂色酮肟衍生物 |
| EP3341353A1 (en) | 2015-08-27 | 2018-07-04 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| EP3356360A1 (en) | 2015-09-28 | 2018-08-08 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| MA43304A (fr) | 2015-11-25 | 2018-10-03 | Genentech Inc | Benzamides substitués utiles en tant que bloqueurs de canaux sodiques |
| EP3436432B1 (en) | 2016-03-30 | 2021-01-27 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| WO2017184774A1 (en) | 2016-04-19 | 2017-10-26 | Acetylon Pharmaceuticals, Inc. | Hdac inhibitors, alone or in combination with btk inhibitors, for treating chronic lymphocytic leukemia |
| WO2018017910A1 (en) | 2016-07-22 | 2018-01-25 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
| BR112019007763A2 (pt) | 2016-10-17 | 2019-07-02 | Genentech Inc | composto de fórmula, composição farmacêutica, métodos para tratar uma doença ou condição, para tratar dores, para diminuir o fluxo de íons e para tratar prurido, uso de um composto e invenção |
| CN110546148A (zh) | 2017-03-24 | 2019-12-06 | 基因泰克公司 | 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物 |
| US12208071B2 (en) | 2018-02-13 | 2025-01-28 | Ligand Pharmaceuticals Incorporated | Glucagon receptor antagonists |
| AR114263A1 (es) | 2018-02-26 | 2020-08-12 | Genentech Inc | Compuestos terapéuticos y métodos para utilizarlos |
| CN111936494A (zh) | 2018-03-30 | 2020-11-13 | 豪夫迈·罗氏有限公司 | 作为钠通道抑制剂的取代的氢-吡啶并-吖嗪 |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE249241C (enExample) | 1910-05-01 | 1912-07-13 | ||
| US3431301A (en) | 1966-03-24 | 1969-03-04 | Hoffmann La Roche | Process for producing methylhydrazine derivatives |
| US3776917A (en) | 1972-06-05 | 1973-12-04 | Schering Corp | 2-amino-6-phenalkyl-aminopyridines and derivatives thereof |
| ES419319A1 (es) | 1973-10-04 | 1976-03-01 | Gallardo Antonio Sa | Un procedimiento para la obtencion de derivados de acidos 3-benzoilfenilalcanoicos. |
| GB8909574D0 (en) | 1989-04-26 | 1989-06-14 | Ici Plc | Chemical process |
| US5169951A (en) | 1990-04-23 | 1992-12-08 | Ciba-Geigy Corporation | Process for preparing nematicidal compositions |
| EP0566138B1 (en) | 1992-04-17 | 1998-11-18 | Hodogaya Chemical Co., Ltd. | Amino thiazole derivatives and their use as fungicides |
| US5556859A (en) | 1994-12-22 | 1996-09-17 | Dowelanco | N-(4-pyrimidinyl)amide pesticides |
| FR2766183B1 (fr) * | 1997-07-17 | 1999-08-27 | Rhone Poulenc Rorer Sa | Medicaments contenant des polyhydroxybutylpyrazines, les polyhydroxybutylpyrazines nouvelles et leur preparation |
| GB9823871D0 (en) | 1998-10-30 | 1998-12-23 | Pharmacia & Upjohn Spa | 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents |
| US6610846B1 (en) | 1999-03-29 | 2003-08-26 | Hoffman-La Roche Inc. | Heteroaromatic glucokinase activators |
| PT1169312E (pt) * | 1999-03-29 | 2005-01-31 | Hoffmann La Roche | Activadores de glicocinase |
| RU2242469C2 (ru) | 1999-03-29 | 2004-12-20 | Ф.Хоффманн-Ля Рош Аг | Активаторы глюкокиназы |
| US6320050B1 (en) | 1999-03-29 | 2001-11-20 | Hoffmann-La Roche Inc. | Heteroaromatic glucokinase activators |
| US6353111B1 (en) | 1999-12-15 | 2002-03-05 | Hoffmann-La Roche Inc. | Trans olefinic glucokinase activators |
| DK1280801T3 (da) * | 2000-05-03 | 2006-01-23 | Hoffmann La Roche | Hydantoinholdige glucokinaseaktivatorer |
| PT1282612E (pt) | 2000-05-03 | 2005-04-29 | Hoffmann La Roche | Actividades heteroaromaticas da glucoquinase a vase de alcinilo-fenilo |
| US6489485B2 (en) | 2000-05-08 | 2002-12-03 | Hoffmann-La Roche Inc. | Para-amine substituted phenylamide glucokinase activators |
| KR100548901B1 (ko) | 2000-05-08 | 2006-02-02 | 에프. 호프만-라 로슈 아게 | 치환된 페닐아세트아미드 및 그의 글루코키나제활성화제로서의 용도 |
| WO2002008209A1 (en) | 2000-07-20 | 2002-01-31 | F. Hoffmann-La Roche Ag | Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators |
| US6369232B1 (en) | 2000-08-15 | 2002-04-09 | Hoffmann-La Roche Inc. | Tetrazolyl-phenyl acetamide glucokinase activators |
| DK1341774T3 (da) | 2000-12-06 | 2006-06-12 | Hoffmann La Roche | Kondenserede heteroaromatiske glucokinase-aktivatorer |
| US6433188B1 (en) | 2000-12-06 | 2002-08-13 | Wendy Lea Corbett | Fused heteroaromatic glucokinase activators |
-
2003
- 2003-12-10 MY MYPI20034740A patent/MY141521A/en unknown
- 2003-12-10 US US10/732,838 patent/US7132425B2/en not_active Expired - Fee Related
- 2003-12-10 PE PE2003001259A patent/PE20040801A1/es not_active Application Discontinuation
- 2003-12-11 BR BR0317268-6A patent/BR0317268A/pt not_active IP Right Cessation
- 2003-12-11 DK DK03767788T patent/DK1572670T3/da active
- 2003-12-11 RU RU2005121667/04A patent/RU2310648C2/ru not_active IP Right Cessation
- 2003-12-11 NZ NZ540298A patent/NZ540298A/en not_active IP Right Cessation
- 2003-12-11 PT PT03767788T patent/PT1572670E/pt unknown
- 2003-12-11 CA CA002506441A patent/CA2506441C/en not_active Expired - Fee Related
- 2003-12-11 JP JP2004558065A patent/JP4490285B2/ja not_active Expired - Fee Related
- 2003-12-11 MX MXPA05006250A patent/MXPA05006250A/es active IP Right Grant
- 2003-12-11 HR HR20050512A patent/HRP20050512A2/hr not_active Application Discontinuation
- 2003-12-11 AR ARP030104577A patent/AR046244A1/es unknown
- 2003-12-11 KR KR1020057010528A patent/KR100743890B1/ko not_active Expired - Fee Related
- 2003-12-11 EP EP03767788A patent/EP1572670B1/en not_active Expired - Lifetime
- 2003-12-11 WO PCT/EP2003/014055 patent/WO2004052869A1/en not_active Ceased
- 2003-12-11 UY UY28121A patent/UY28121A1/es not_active Application Discontinuation
- 2003-12-11 TW TW092135035A patent/TW200426139A/zh unknown
- 2003-12-11 AU AU2003292229A patent/AU2003292229B2/en not_active Ceased
- 2003-12-11 DE DE60315886T patent/DE60315886T2/de not_active Expired - Lifetime
- 2003-12-11 PL PL377551A patent/PL377551A1/pl not_active Application Discontinuation
- 2003-12-11 ES ES03767788T patent/ES2291697T3/es not_active Expired - Lifetime
- 2003-12-11 AT AT03767788T patent/ATE370936T1/de active
- 2003-12-11 PA PA20038592001A patent/PA8592001A1/es unknown
-
2005
- 2005-05-26 NO NO20052555A patent/NO330139B1/no not_active IP Right Cessation
-
2007
- 2007-11-08 CY CY20071101430T patent/CY1106989T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200426139A (en) | 5-substituted-six-membered heteroaromatic glucokinase activators | |
| TWI229078B (en) | Glucokinase activators | |
| TWI281917B (en) | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | |
| US11718631B2 (en) | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | |
| US6265436B1 (en) | Substituted 5-biphenyl-3,4-dihydroxy-2(5H)-furanones and method of use therefor | |
| EP3057962B1 (en) | Hydrochloride salt form for ezh2 inhibition | |
| CN104230793A (zh) | 调控激酶级联的组合物以及方法 | |
| CN100439357C (zh) | 苯并[b][1,4]二氧杂环庚三烯衍生物 | |
| JP2009514837A (ja) | グルコキナーゼ調節物質としてのトリシクロ置換アミド | |
| EP2154130A1 (en) | Pyridone compound | |
| KR100517452B1 (ko) | 치환 비닐피리딘 유도체 및 이를 함유하는 의약 | |
| WO2013061005A1 (fr) | Composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines | |
| WO2012155806A1 (zh) | 4-氨基喹唑啉衍生物及其应用 | |
| TW201710249A (zh) | 飢餓素ｏ－醯基轉移酶抑制劑 | |
| US20110112151A1 (en) | Compound capable of inhibiting 11-beta hydroxysteriod dehydrogenase | |
| JP2005508951A (ja) | 化合物および方法 | |
| WO2001032633A1 (de) | Substituierte 5-benzyl-2,4-diaminopyrimidine | |
| JPH09503503A (ja) | 化合物、組成物ならびにアレルギーおよび炎症の治療 | |
| CA2859586C (en) | Bisarylsulfonamides useful in the treatment of inflammation and cancer | |
| CA2058651A1 (en) | Sulphonamide derivatives | |
| TW201602089A (zh) | 多環性ｈｅｒｇ活化劑 | |
| CN102485717B (zh) | 噻唑胺衍生物及其作为抗小rna病毒感染药物的用途 | |
| WO2024050434A1 (en) | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES | |
| CN100469770C (zh) | 5-取代的-吡嗪或吡啶葡糖激酶激活剂 | |
| CN116157120A (zh) | 包含苯并呋喃基n-酰腙衍生物的抗炎组合物 |